While newly developed technologies have revolutionized the classical approaches to combating infectious diseases, the difficulties associated with developing novel antimicrobials mean that these technologies have not yet been used to introduce new compounds into the market. The new technologies, including genomics and structural biology, open up exciting possibilities for the discovery of antibiotics. However, a substantial effort to pursue research, and moreover to incorporate the results into the production chain, is required in order to bring new antimicrobials to the final user. In the current scenario of emerging diseases and the rapid spread of antibiotic resistance, an active policy to support these requirements is vital. Otherwise, many valuable programmes may never be fully developed for lack of "interest'' and funds (private and public). Will we react in time to avoid potential disaster?.
The Fallacies of Hope: will we discover new antibiotics to combat pathogenic bacteria in time? / Vicente, M; Hodgson, J; Massidda, Orietta; Tonjum, T; Henriques-Normark, B; Ron, E. Z.. - In: FEMS MICROBIOLOGY REVIEWS. - ISSN 0168-6445. - 30:6(2006), pp. 841-852. [10.1111/j.1574-6976.2006.00038.x]
The Fallacies of Hope: will we discover new antibiotics to combat pathogenic bacteria in time?
Massidda, Orietta;
2006-01-01
Abstract
While newly developed technologies have revolutionized the classical approaches to combating infectious diseases, the difficulties associated with developing novel antimicrobials mean that these technologies have not yet been used to introduce new compounds into the market. The new technologies, including genomics and structural biology, open up exciting possibilities for the discovery of antibiotics. However, a substantial effort to pursue research, and moreover to incorporate the results into the production chain, is required in order to bring new antimicrobials to the final user. In the current scenario of emerging diseases and the rapid spread of antibiotic resistance, an active policy to support these requirements is vital. Otherwise, many valuable programmes may never be fully developed for lack of "interest'' and funds (private and public). Will we react in time to avoid potential disaster?.File | Dimensione | Formato | |
---|---|---|---|
Vicente et al._FEMS Microbiol Rev_2006.pdf
Solo gestori archivio
Tipologia:
Versione editoriale (Publisher’s layout)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
286.5 kB
Formato
Adobe PDF
|
286.5 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione